Lonza has today released the latest addition to its L7™ hPSC System, a robust, streamlined and comprehensive platform for the generation of human induced pluripotent stem cells (hiPSCs) and the maintenance of stem cells from a variety of sources. The new L7™ PBMC Reprogramming Bundle slots seamlessly into the existing L7™ workflow to enable researchers to reprogram peripheral blood mononuclear cells (PBMCs) for use in downstream experiments. Because of its series of reagents and protocols optimized for working specifically with PBMCs, the new bundle makes it easier and faster to generate hiPSCs. The L7™ hPSC System offers a complete workflow that combines primary cells, reprogramming kits, transfection tools and culturing media, along with a matrix, passaging solution and cryosolution. As such, it streamlines the reprogramming of somatic cells to generate hiPSCs, as well as supporting the ongoing maintenance and utilization of human embryonic stem cells (hESCs) and hiPSCs.
Newly Enhanced ...